1. Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment
2. Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial
3. Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial
4. FDA. Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee meeting announcement. 24 May 2024. https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-24-2024-meeting-endocrinologic-and-metabolic-drugs-advisory-committee-meeting-announcement
5. NHS England. Hybrid closed loop technology. https://www.england.nhs.uk/diabetes/digital-innovations-to-support-diabetes-outcomes/hybrid-closed-loop-technology